| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160349.txt","as_of":"2026-04-18T03:05:05.644967+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160349.txt","company":"Viridian Therapeutics, Inc.\\DE","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160349.txt","article_chars":1964,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_c275815294afddef","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160349.txt","content_type":"text/plain","enriched_at":"2026-04-18T03:19:59.131994+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"DEFA14A","final_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160349.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160349.txt","source_event_id":"evt_87466dad76c5","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEFA14A","fp":"6814e3ce280c9a73","kind":"sec_filing","published_at":"20260417","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-17","June 2, 2026","May 19, 2026"],"entities":[{"asset_class":"equity","name":"Viridian Therapeutics, Inc.","relevance":"high","symbol":"","type":"issuer"}],"event_type":"listing","information_gaps":["No specific proxy proposals, resolutions, or voting items are included in the provided text (only an overview/availability notice).","The filing\u2019s \u201cAmendment No.\u201d value is blank in the provided text.","No prior known state is provided in the prompt, so the exact delta vs prior filings cannot be determined from the supplied content."],"key_facts":["The document is a Schedule 14A information statement (proxy statement) under Section 14(a) of the Securities Exchange Act of 1934.","The filing indicates it is filed by the registrant (\u2612 Filed by the Registrant).","The notice states the stockholder meeting will be held on June 2, 2026.","The notice states stockholders can view the proxy statement, notice, and annual report online or request free paper/email copies.","The notice states requests for paper/email copies must be made prior to May 19, 2026.","The notice provides access/request methods: www.ProxyVote.com, call 1-800-579-1639, or email sendmaterial@proxyvote.com (with a control number in the subject line).","The notice states: \u201cTHIS IS NOT A VOTABLE BALLOT\u201d and that it is only an overview of more complete proxy materials."],"numeric_claims":[{"label":"Annual meeting date","value":"June 2, 2026"},{"label":"Request deadline for paper/email copies","value":"May 19, 2026"}],"primary_claim":"Viridian Therapeutics, Inc. filed Form DEFA14A (Schedule 14A information) on 2026-04-17, with proxy materials for a stockholder meeting scheduled for June 2, 2026.","relevance_score":0.45,"sentiment":"neutral","source_quality":"medium","summary":"Viridian Therapeutics, Inc. filed a Schedule 14A proxy-related filing (DEFA14A) providing notice of the availability of proxy materials for a stockholder meeting. The notice states the annual meeting will be held on June 2, 2026 and describes how to access or request the proxy materials.","topics":["SEC filing","proxy statement","Schedule 14A","stockholder meeting notice","proxy materials availability"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEFA14A \u00b7 Viridian Therapeutics, Inc.\\DE \u00b7 Filed 20260417","ticker":"VRDN","tickers":["VRDN"],"title":"VRDN filed DEFA14A","url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160349.txt"}... |